An internal standard for the quantification of DHA by GC- or LC-MS.

A chromogenic substrate for endoglucanases and cellobiohydrolases.

An inhibitor of Cdc7 kinase (IC₅₀ = 10 nM) as well as Cdk9, (IC₅₀ = 34 nM); induces apoptotic cell death in multiple cancer cell types at 10 µM.

A natural anthocyanin that has neuroprotective effects, reducing amyloid β-induced cytotoxicity in Neuro-2A cells; stimulates autophagy in U2OS cells.

A selective calcium ionophore that mobilizes intracellular calcium stores. It is used as a research tool to raise the intracellular level of calcium, to study calcium transport across biological membranes, and to stimulate the intracellular production of cytokines.

A certified reference material categorized as a phytocannabinoid; intended for research and forensic applications

A stable, cell-permeable molecule that generates free α-ketoglutarate upon hydrolysis by cytoplasmic esterases; used in experiments to increase levels of intracellular α-ketoglutarate and modulate a variety of enzymes, particularly in the context of glycolysis, hypoxia, and cancer.

A physiologically active metabolite of losartan; a potent AT1 antagonist (Kis = 0.57 and 0.67 nM for rat and human forms, respectively), producing a depressor response and vasodilatation.

A selective calcium ionophore that mobilizes intracellular calcium stores. It is used as a research tool to raise the intracellular level of calcium, to study calcium transport across biological membranes, and to stimulate the intracellular production of cytokines.

A glutamine analog that irreversibly inhibits glutamine-dependent amidotransferases involved in nucleotide and amino acid biosynthesis (Kis = 10 and 560 μM for anthranilate synthase and glutamate synthase, respectively); reversibly inhibits γ-glutamyl transpeptidase.

13(S)-HODE is the LO metabolite of linoleic acid. 13(S)-HODE modulates the PAF, LTB4, and fMLP-induced calcium influx in human PMNL. The mechanism by which 13(S)-HODE elicits its inhibitory effect is still unclear. The use of biotinylated 15(S)-HETE as a probe for detecting binding proteins and/or…

A potent marine-derived neurotoxin that reversibly inhibits the inward sodium current through NaV channels (IC₅₀s = 4.1 and 5.2 nM, respectively, in frog muscle and squid axon; Kd = 1.8 nM in rat brain), blocking nerve and muscle action potentials.

A certified reference material categorized as a phytocannabinoid; a common component of hashish but is not psychoactive until heating, which converts it to ?9-THC; provided as a DEA exempt preparation; intended for research and forensic applications

An inhibitor of both CDK1 and CDK2 (IC₅₀s =2.9 and 2.2 µM, respectively); inhibits cellular ataxia telangiectasia mutated and Rad3-realted kinase activity (IC₅₀ = 6.7 µM) and impairs G2/M arrest in various human cancer cells, potentiating the cytotoxic effects of…

A small molecule inhibitor of human cytomegalovirus viral replication (EC₅₀ = ~5 nM with a selectivity index >15,000) that targets viral DNA cleavage and packaging.

A natural type B trichothecene produced by certain species of the fungus Fusarium; inhibits protein biosynthesis, binds to peptidyl transferase, and inhibits the synthesis of RNA and DNA; passes the blood-brain barrier at different rates in different animals.

A small molecule, multi-targeted receptor tyrosine kinase inhibitor; potently inhibits signaling through PDGFR, VEGFR, KIT, and FLT3; inhibits both tumor cell growth and angiogenesis; approved by the FDA for the treatment of gastrointestinal stromal tumor and metastatic renal cell carcinoma.

CAS Number: 883986-34-3 Molecular Formula: C₂₄H₂₅N₅O₄ Formula Weight: 447.5

Butaprost is a structural analog of PGE2 with good selectivity for the EP2 receptor subtype. Butaprost has frequently been used to pharmacologically define the EP receptor expression profile of various human and animal tissues and cells. Serious confusion as to the structure of Butaprost was…

An irreversible inhibitor of BMX (IC₅₀ = 8 nM) and BTK (IC₅₀ = 10.4 nM); inhibits the proliferation of Tel-BMX-transformed Ba/F3 prostate cancer cells (GI₅₀ = 25 nM), as well as RV-1, DU-145, PC-3, and VCAP prostate cancer cell lines (GI₅₀s = 2.54, 4.38,…

An inhibitor of PAD4 deimination activity (IC50 = 5.9 μM) that also inhibits PAD1 and PAD3 (IC50 = 0.8 and 6.2 μM, respectively); dose dependently decreases the citrulline content in serum and joints and reduces the development of IgG autoantibodies in a CIA mouse model of inflammatory arthritis.

A selective inhibitor of cFMS kinase (IC₅₀ = 0.03 μM) that prevents CSF-1-induced monocyte growth with an IC₅₀ value of 0.14 μM; at 75-100 mg/kg, inhibits joint connective tissue and bone degradation in mouse models of arthritis.

An internal standard for the quantification of 5-POHSA by GC- or LC-MS.

A small molecule activator of AMPK that stimulates functional activation of AMPK in cultured muscle cells (EC50 = 4.3 μM), enhancing glucose uptake by 3.2-fold; 10 mg/kg up-regulates the activity of AMPK in the liver and muscle of diet-induced obese mice, enhancing insulin sensitivity and…

An orally active inhibitor of PI3Kg that suppresses joint inflammation in mouse models of rheumatoid arthritis; inhibits human recombinant PI3Kg, a, b, and d in an ATP-competitive manner with IC50 values of 8, 60, 270, and 300 nM, respectively.

A potent inhibitor of both MEK 1 and 2 that works in an ATP-noncompetitive fashion (IC₅₀s = 0.7 and 0.9 nM, respectively); blocks dual phosphorylation of ERK1/2 and stops cell cycling in cancer cell lines, both in vitro and in multiple tumor models in mice.

A selective, reversible inhibitor of vacuolar H+-ATPases (V-ATPases), blocking these proton pumps in mammalian, plant, or fungal cells with an IC50 value in the 4-400 nM range; also inhibits autophagy by preventing vacuolar acidification necessary for autophagosome maturation.

A selective inhibitor of ABHD6 (IC₅₀ = 10 nM) with negligible activity against other serine hydrolases such as DAGLβ; used both as a probe to study ABHD6 and as a negative control for studies of DAGLβ.

An inhibitor of p53-HDM-2 interaction that can reactivate the tumor suppressor function of wild-type p53; binds to p53 with an apparent Kd value of 1.5 nM and prevents interaction with HDM-2 resulting in p53 stabilization, accumulation, and activation.

A major phase I metabolite of tamoxifen, a well-known estrogen receptor antagonist in breast but partial estrogen receptor agonist in endometrium; has at least a 100-fold higher affinity for estrogen receptors than tamoxifen.

A potent inhibitor of all three human Pim kinases (IC₅₀s = 7, 363, and 69 nM for Pim-1, Pim-2, and Pim-3, respectively); induces apoptosis in lymphocytes from patients with CML or ALL; enhances the activity of sunitinib against renal cell carcinoma and resensitizes chemoresistant cancer…

A potent, ATP-competitive inhibitor of ROCKs including p160ROCK (Ki = 140 nM) and ROCK-II (IC50 = 800 nM); also inhibits PRK2 with an IC50 value of 600 nM.